Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Trial details
- Registry ID
- NCT06757634
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as KISQALI®, Faslodex
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)NCT06757634 | CELC | Phase 3 | Recruiting | 2029-03-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |